A culture medium for constructing organoid models of central nervous system lymphoma and its application.
By constructing organoid models of central nervous system lymphomas using a specific culture medium composition and mechanical dissociation method, the problem of poor model consistency in existing technologies has been solved, achieving efficient and stable organoid construction and biological similarity, supporting precision treatment and drug screening.
Patent Information
- Application Number
- CN202611286221.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies for constructing central nervous system lymphoma (PCNSL) models suffer from problems such as limited cell line types, loss of heterogeneity, high cost of animal models, and difficulty in simulating the human immune microenvironment, resulting in poor consistency between drug screening results and clinical responses. Traditional organoid culture also suffers from low success rates and lack of key components such as immune cells.
Using a specific culture medium composition, including DMEM/F12 basal medium containing B27, N2, L-glutamine, penicillin-streptomycin, EGF, bFGF, ROCK inhibitor, NAC, BAFF, etc., a central nervous system lymphoma organoid model was constructed by mechanical dissociation and culture medium resuspension, preserving immune cells and reproducing the tumor immune microenvironment.
It significantly improved the success rate of PCNSL organoid culture and passage stability. The constructed organoids are highly biologically similar to in vivo tissues, with consistent morphology, molecular phenotype and pathological characteristics, providing a reliable model for precision treatment and drug screening.
Smart Images

Figure CN123107905A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of organoid model construction technology, specifically to a culture medium for constructing a central nervous system lymphoma organoid model and its application. Background Technology
[0002] Primary central nervous system lymphoma (PCNSL) is a highly aggressive type of extranodal non-Hodgkin lymphoma, with over 90% being the diffuse large B-cell lymphoma (DLBCL) subtype, the vast majority of which belong to the activated B-cell-like (ABC) / non-germinal center subtype. It is often accompanied by high-frequency mutations such as MYD88 L265P and CD79B. Due to the presence of the blood-brain barrier, the high heterogeneity of tumors, and the unique immune microenvironment of the central nervous system, an ideal model for the clinical treatment and basic research of PCNSL has long been lacking.
[0003] Currently, preclinical studies of PCNSL mainly rely on traditional cell lines and animal models, but these models have significant limitations:
[0004] 1) Currently, there are relatively few cell lines available for PCNSL, with the main cell lines including HKBML and TK. However, long-term in vitro passage of cell lines leads to the loss of tumor heterogeneity, making it impossible to simulate the real biological behavior in patients. For example, key pathological features such as cell interactions and perivascular infiltration in the tumor microenvironment (TME) result in poor consistency between drug sensitivity screening results and clinical responses.
[0005] 2) Animal models: They have long construction cycles, high costs, large individual differences, and are difficult to accurately simulate the human immune microenvironment, which limits the efficacy evaluation of immunotherapy and combination therapy.
[0006] In recent years, patient-derived organoid (PDO) technology has provided more clinically relevant models for tumor research. However, existing PCNSL organoid construction technologies still have the following drawbacks: Low culture success rate: PCNSL tumor cells are fragile and sensitive to dissociation conditions, matrix, and culture medium components, and most samples cannot form stable passaged organoids. Lack of microenvironment: Traditional organoids only contain tumor cells and lack key components such as immune cells and vascular endothelial cells, failing to simulate the tumor's immune microenvironment and leading to insufficient reliability of research results. Summary of the Invention
[0007] The purpose of this invention is to provide a culture medium for constructing a central nervous system lymphoma (PCNSL) organoid model and its application. The culture medium of this invention can efficiently, stably, and reproducibly construct PCNSL organoids, significantly improving the success rate of PCNSL organoid culture and passage stability. In addition, the constructed PCNSL lymphoma organoids have a high degree of biological similarity to in vivo PCNSL lymphoma tissues, and are highly consistent with the in situ tumors in terms of morphology, molecular phenotype, and pathological characteristics, providing a reliable model for PCNSL precision treatment and drug screening.
[0008] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted:
[0009] The first aspect of this invention provides a culture medium for constructing a central nervous system lymphoma organoid model, wherein the culture medium has the following composition by volume:
[0010] 1×B27 serum-free additive, 1×N2 additive, 1×L-glutamine, 1×non-essential amino acid, 1×penicillin-streptomycin, EGF 10~20ng / mL, bFGF 10~20ng / mL, ROCK inhibitor 10~20μM, NAC 1~5 mM, BAFF 10~20ng / mL, 1×ITS-A additive, with the remainder being DMEM / F12 basal medium.
[0011] Preferably, the culture medium has the following composition by volume:
[0012] 1×B27 serum-free additive, 1×N2 additive, 1×L-glutamine, 1×non-essential amino acid, 1×penicillin-streptomycin, EGF 20ng / mL, bFGF 20ng / mL, ROCK inhibitor 10μM, NAC 1 mM, BAFF 10ng / mL, 1×ITS-A additive, with the remainder being DMEM / F12 basal medium.
[0013] A second aspect of the present invention provides the application of the above-mentioned culture medium in a constructed central nervous system lymphoma organoid model.
[0014] A third aspect of the present invention provides a method for constructing an organoid model of central nervous system lymphoma, the method comprising the following steps:
[0015] (a) Mechanically dissociate PCNSL samples into small cell clusters;
[0016] (b) The PCNSL cell clusters were resuspended in the culture medium and cultured with the culture medium to obtain the central nervous system lymphoma organoid model.
[0017] Preferably, in step (b), the culture time is 7 to 14 days; the culture medium is changed every 2 to 3 days during the culture process.
[0018] The fourth aspect of the present invention provides a central nervous system lymphoma organoid model constructed by the above-described construction method.
[0019] Compared with the prior art, the beneficial effects of the present invention include at least the following:
[0020] The culture medium of this invention enables efficient, stable, and reproducible construction of PCNSL organoids, and significantly improves the success rate and passage stability of PCNSL organoids. In addition, by preserving immune cells through co-mechanical dissociation, the intratumoral immune microenvironment is reproduced, resulting in organoid models containing the tumor microenvironment. The constructed central nervous system lymphoma organoids have a high degree of biological similarity to in vivo central nervous system lymphoma tissues, and are highly consistent with the in situ tumors in terms of morphology, molecular phenotype, and pathological features, providing a reliable model for precision treatment and drug screening of PCNSL. Attached Figure Description
[0021] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the accompanying drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to scale.
[0022] Figure 1 Images of organoids constructed for PCNSL clinical samples;
[0023] Figure 2 Comparative organoid images constructed for PCNSL clinical samples;
[0024] Figure 3 Immunofluorescence assay of organoids constructed for PCNSL clinical samples to detect the expression of Ki67 and CD20.
[0025] Figure 4 Organoid survival rate was measured 3 days after drug treatment for organoids constructed for PCNSL clinical samples. Detailed Implementation
[0026] The embodiments of the technical solution of the present invention will be described in detail below with reference to the examples. The following embodiments are only used to illustrate the technical solution of the present invention more clearly, and are therefore only examples, and should not be used to limit the scope of protection of the present invention.
[0027] It should be noted that, unless otherwise stated, the technical or scientific terms used in this application should have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.
[0028] This invention provides a culture medium for constructing a central nervous system lymphoma organoid model, the composition of which, by volume, is as follows:
[0029] 1×B27 serum-free additive, 1×N2 additive, 1×L-glutamine, 1×non-essential amino acid, 1×penicillin-streptomycin, EGF 10~20ng / mL, bFGF 10~20ng / mL, ROCK inhibitor 10~20μM, NAC 1~5 mM, BAFF 10~20ng / mL, 1×ITS-A additive, with the remainder being DMEM / F12 basal medium.
[0030] In one embodiment, the culture medium has the following composition by volume:
[0031] 1×B27 serum-free additive, 1×N2 additive, 1×L-glutamine, 1×non-essential amino acid, 1×penicillin-streptomycin, EGF 20ng / mL, bFGF 20ng / mL, ROCK inhibitor 10μM, NAC 1 mM, BAFF 10ng / mL, 1×ITS-A additive, with the remainder being DMEM / F12 basal medium.
[0032] In the culture medium of this invention, the content of penicillin is 100 U / mL and the content of streptomycin is 100 µg / mL.
[0033] In one embodiment, the ROCK inhibitor is Y-27632.
[0034] Another embodiment of the present invention provides the application of the above-mentioned culture medium in constructing a central nervous system lymphoma organoid model.
[0035] Another embodiment of the present invention provides a method for constructing a central nervous system lymphoma organoid model, the method comprising the following steps:
[0036] (a) Mechanically dissociate PCNSL samples into small cell clusters;
[0037] (b) The PCNSL cell clusters were resuspended in the culture medium and cultured with the culture medium to obtain the central nervous system lymphoma organoid model.
[0038] In one embodiment, in step (b), the culture time is 7 to 14 days; the culture medium is changed every 2 to 3 days during the culture process.
[0039] Another embodiment of the present invention provides a central nervous system lymphoma organoid model constructed by the above construction method.
[0040] The technical solution of the present invention will be further described below through specific embodiments.
[0041] Example 1
[0042] This embodiment describes a culture medium for constructing a central nervous system lymphoma organoid model. The composition of the culture medium, by volume, is as follows:
[0043] 1×B27 serum-free additive (diluted to 1X working concentration with 50X stock solution; 50X stock solution is Gibco product number 17504044), 1×N2 additive (diluted to 1X working concentration with 100X stock solution; 100X stock solution is Gibco product number 17502048), 1×L-glutamine (diluted to 1X working concentration with 100X stock solution; 100X stock solution is Gibco product number 35050061), 1×non-essential amino acid (diluted to 1X working concentration with 100X stock solution; 100X stock solution is Gibco product number 11140050), 1×penicillin-streptomycin (100X stock solution is Thermo product number 15140122), EGF 20 ng / mL, bFGF 20 ng / mL, ROCK inhibitor (Y-27632) 10 μM, NAC 1 mM, BAFF 10 ng / mL, 1×ITS-A additive (100X stock solution diluted to 1X working concentration, 100X stock solution is Thermo product with product number 51300044), the balance is DMEM / F12 basal medium.
[0044] Example 2
[0045] This embodiment describes a method for constructing an organoid model of central nervous system lymphoma, which includes the following steps:
[0046] (a) Tumor tissue obtained from PCNSL patients surgically removed by the Department of Neurosurgery at Tiantan Hospital (with ethical approval and informed consent from the patients), pathologically diagnosed as diffuse large B-cell lymphoma (non-germinal center type); the surgically removed PCNSL tissue was obtained under aseptic conditions, washed twice with pre-cooled PBS, and minced to 0.5-1 mm. 3 Small pieces were prepared into cell cluster suspensions; the cell clusters were resuspended in the culture medium of Example 1 and seeded into 6-well ultra-low adsorption plates, with 15 to 30 cell clusters seeded into each well;
[0047] (b) Add 3 mL of the culture medium from Example 1 to each well, place it on a track shaker and incubate at 37°C and 5% CO2 for 10 days. Change the culture medium every 2 days to obtain the central nervous system lymphoma organoid model.
[0048] Comparative Example 1
[0049] This comparative example is a culture medium used to construct a central nervous system lymphoma organoid model. This culture medium is basically the same as the culture medium in Example 1, except that NAC and BAFF are not added.
[0050] Comparative Example 2
[0051] This comparative example is a culture medium used to construct a central nervous system lymphoma organoid model. This culture medium is basically the same as the culture medium in Example 1, except that BAFF is not added.
[0052] Comparative Example 3
[0053] This comparative example is a culture medium used to construct a central nervous system lymphoma organoid model. This culture medium is basically the same as that of Comparative Example 2, except that the DMEM / F12 basal medium is replaced with DMEM / F12:NeurobasalMedium 1:1 basal medium.
[0054] Comparative Example 4
[0055] This comparative example illustrates a method for constructing an organoid model of central nervous system lymphoma, which includes the following steps:
[0056] (a) Tumor tissue obtained from PCNSL patients surgically removed by the Department of Neurosurgery at Tiantan Hospital (with ethical approval and informed consent from the patients), pathologically diagnosed as diffuse large B-cell lymphoma (non-germinal center type); under sterile conditions, the surgically removed PCNSL tissue was obtained, washed twice with pre-cooled PBS, and enzymatically digested to prepare a cell suspension; the prepared cell suspension was mixed with Matrigel at a ratio of 1:1, seeded into 24-well ultra-low adsorption plates, 50 μL of the mixture per well, and incubated at 37°C for 30 min until Matrigel solidified;
[0057] (b) After incubation, add 500 μL of the culture medium from Example 1 and incubate at 37°C in a 5% CO2 incubator for 10 days, changing the culture medium every 2 days.
[0058] Experimental Example
[0059] 1. Using the construction method of Example 2, central nervous system lymphoma organoid models were constructed from tumor tissues from two patients (denoted as PDO#1 and PDO#2), after culturing for approximately 7 days, 14 days, and 19 days as described in step (b). Around day 7 of culture, dense solid spheres with a diameter of approximately 200-300 μm were observed; around day 14, the diameter reached 400-500 μm, with invasive pseudopodia visible at the edges. Microscopic observation results are as follows... Figure 1 As shown;
[0060] Depend on Figure 1 It can be seen that the tumor cells are densely packed with a high nucleoplasm-to-cytoplasm ratio, reproducing the structural characteristics of PCNSL.
[0061] 2. Using the construction method of Comparative Example 4, a central nervous system lymphoma organoid model was constructed after 7 days of culture. On day 7 of culture, dense solid spheres with a diameter of approximately 100-200 μm were observed to form. Microscopic observation results are as follows: Figure 2 The image shown is for comparison #4;
[0062] Depend on Figure 1 , 2 It can be seen that the organoids constructed using the construction method of Comparative Example 4 grow slower and have smaller volumes than the organoids constructed using the construction method of Example 2.
[0063] 3. Using the construction method of Example 2, the culture medium used in the construction method of Example 2 was replaced with the culture medium of Comparative Examples 1-3, and the central nervous system lymphoma organoid models were constructed. After culturing for 7 days, the constructed central nervous system lymphoma organoid models were sequentially described as follows: Figure 2 The images shown are for comparison #1, #2, and #3.
[0064] Depend on Figure 1 , 2 It can be known that:
[0065] The organoids constructed using the culture medium of Example 1 grew faster and had larger organoid volumes.
[0066] 4. CD20 of the central nervous system lymphoma organoid models (PDO#1 and PDO#2 tumor tissue sources) constructed in Example 2 + The expression of Ki-67 was detected, and the immunofluorescence results were as follows: Figure 3 As shown;
[0067] Depend on Figure 3 It can be known that:
[0068] Central nervous system lymphoma organoid model expressing CD20 +Ki-67 is highly consistent with the high expression of CD20 and Ki-67 in clinical central nervous system lymphomas.
[0069] 5. Using the construction method of Example 2, a central nervous system lymphoma organoid model rich in immune microenvironment was constructed for drug sensitivity screening:
[0070] Drug treatment: PCNSL organoids cultured for 10 days in Example 2 were selected and divided into a control group (DMSO), an ibrutinib (1 μM) group, and a zanubrutinib (1 μM) group; organoid cell viability was detected 3 days after drug treatment.
[0071] The results are as follows Figure 4 As shown, Figure 4 Image A shows the morphology of PCNSL organoids cultured for 10 days after treatment with the control group (DMSO), ibrutinib (1 μM), and zanubrutinib (1 μM). Image B shows the cell viability of the organoids.
[0072] Depend on Figure 4 It can be seen that the ibrutinib group showed a reduction in organoid volume, indicating significant inhibition of organoid growth; the zanubrutinib group also showed a reduction in volume, indicating significant inhibition of organoid growth; consistent with the patients' clinical response; while the control group showed continuous organoid growth.
[0073] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and specification of the present invention.
Claims
1. A medium for constructing a central nervous system lymphoma organoid model, characterized by, The culture medium is composed of the following components by volume: 1× B27 serum-free supplement, 1× N2 supplement, 1× L-glutamine, 1× non-essential amino acids, 1× penicillin-streptomycin, EGF 10~20 ng / mL, bFGF 10~20 ng / mL, ROCK inhibitor 10~20 μM, NAC 1~5 mM, BAFF 10~20 ng / mL, 1× ITS-A supplement, and the balance being DMEM / F12 base medium.
2. The medium of claim 1, wherein, The culture medium is composed of the following components by volume: 1× B27 serum-free supplement, 1× N2 supplement, 1× L-glutamine, 1× non-essential amino acids, 1× penicillin-streptomycin, EGF 20 ng / mL, bFGF 20 ng / mL, ROCK inhibitor 10 μM, NAC 1 mM, BAFF 10 ng / mL, 1× ITS-A supplement, and the balance being DMEM / F12 base medium.
3. The culture medium of claim 1 or 2 for use in constructing a central nervous system lymphoma organoid model.
4. A method of constructing a central nervous system lymphoma organoid model, comprising, The constructing method comprises the following steps: (a) mechanically dissociating a PCNSL sample into small cell clusters; (b) resuspending the PCNSL cell clusters using the culture medium of claim 1 or 2, adding the culture medium of claim 1 or 2 for culture, thereby obtaining the central nervous system lymphoma organoid model.
5. The construction method according to claim 4, characterized in that, In the step (b), the culture time is 7~14 d; and the culture medium is replaced once every 2~3 d during the culture.
6. The central nervous system lymphoma organoid model constructed by the constructing method of any one of claims 4~5.
